Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Metastatic Colorectal Cancer Biomarker Study
NCT02402036Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Feb 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in colorectal cancer (CRC), sponsored by Georgetown University. Primary endpoint: Serum microRNA Quantification at 2 years. Started Feb 2015; status: terminated.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02402036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02402036.